TABLE OF CONTENTS
1 INTRODUCTION 39
1.1 OBJECTIVES OF THE STUDY 39
1.2 MARKET DEFINITION 39
1.3 OVERVIEW OF EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET 39
1.4 LIMITATIONS 41
1.5 MARKETS COVERED 41
2 MARKET SEGMENTATION 44
2.1 MARKETS COVERED 44
2.2 GEOGRAPHICAL SCOPE 45
2.3 YEARS CONSIDERED FOR THE STUDY 46
2.4 CURRENCY AND PRICING 46
2.5 DBMR TRIPOD DATA VALIDATION MODEL 47
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 50
2.7 MULTIVARIATE MODELLING 51
2.8 DISTRIBUTION CHANNEL LIFELINE CURVE 51
2.9 DBMR MARKET POSITION GRID 52
2.10 VENDOR SHARE ANALYSIS 54
2.11 MARKET END USER COVERAGE GRID 55
2.12 SECONDARY SOURCES 56
2.13 ASSUMPTIONS 56
3 EXECUTIVE SUMMARY 57
4 PREMIUM INSIGHTS 61
4.1 PORTERS FIVE FORCES 63
4.2 PESTEL ANALYSIS 64
4.3 ANNUAL TEST VOLUME: FOR ALL COUNTRIES 65
4.3.1 CEPHEID 65
4.3.2 THERMO FISHER SCIENTIFIC INC. 66
4.3.3 HOLOGIC, INC. 67
4.3.4 BD 68
4.3.5 F. HOFFMANN-LA ROCHE LTD 69
4.4 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY 70
4.5 DISTRIBUTORS 71
4.5.1 NORTH AMERICA 71
4.5.2 EUROPE 72
4.5.3 SOUTH ASIA 74
4.5.4 SOUTH EAST ASIA 75
4.5.5 MIDDLE EAST 77
4.5.6 AFRICA 78
5 REGULATORY FRAMEWORK 79
6 MARKET OVERVIEW 82
6.1 DRIVERS 84
6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES 84
6.1.2 IMPROVING DIAGNOSIS SEEKING RATE 84
6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS 85
6.1.4 RISING GERIATRIC POPULATION ACROSS GLOBE 85
6.1.5 RISING PREFERENCE FOR HOMECARE TESTING 86
6.2 RESTRAINTS 87
6.2.1 PRODUCT RECALLS 87
6.2.2 HIGH COSTS OF PRODUCTS 87
6.2.3 NON-AVAILABILITY OF RELEVANT AND APPROPRIATE KITS 88
6.3 OPPORTUNITIES 88
6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS 88
6.3.2 RISING HEALTHCARE EXPENDITURE 89
6.3.3 PANDEMIC OUTBREAK OF COVID-19 90
6.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS 90
6.4 CHALLENGES 91
6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES 91
6.4.2 LACK OF ACCESSIBILITY 91
7 IMPACT OF COVID-19 ON THE EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET 93
7.1 IMPACT ON PRICE 93
7.2 IMPACT ON DEMAND 93
7.3 IMPACT ON SUPPLY CHAIN 94
7.4 KEY INITIATIVES BY MARKET PLAYERS DURING THE COVID 19 94
7.5 CONCLUSION: 95
8 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT 96
8.1 OVERVIEW 97
8.2 CONSUMABLES & REAGENTS 100
8.3 INSTRUMENTS 100
8.3.1 MOBILE PLATFORM (SMALL & PORTABLE) 101
8.3.2 FACILITY-BASED PLATFORMS (LARGE POCT PLATFORM) 101
9 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION 102
9.1 OVERVIEW 103
9.2 RESPIRATORY INFECTIONS TESTING 106
9.2.1 COVID-19 107
9.2.2 FLU B 107
9.2.3 FLU A 107
9.2.4 RSV 107
9.2.5 TUBERCULOSIS 107
9.2.6 PNEUMONIA (PNEUMOCOCCAL PNEUMONIA) 107
9.2.7 OTHERS 108
9.3 SEXUALLY TRANSMITTED INFECTION (STI) TESTING 108
9.3.1 TV 109
9.3.2 CT 109
9.3.3 NG 109
9.3.4 HPV 109
9.3.5 HSV 109
9.3.6 MG 109
9.3.7 UU 110
9.3.8 MH 110
9.3.9 OTHERS 110
9.4 GASTROINTESTINAL TRACT INFECTIONS TESTING 110
9.4.1 GROUP B STREPTOCOCCUS 111
9.4.2 SHIGA TOXIN 111
9.4.3 H. PYLORI 111
9.5 OTHERS 112
10 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER 113
10.1 OVERVIEW 114
10.2 LABORATORIES 117
10.2.1 POLYMERASE CHAIN REACTION 118
10.2.2 ISOTHERMAL AMPLIFICATION 118
10.3 HOSPITAL 118
10.3.1 POLYMERASE CHAIN REACTION 119
10.3.2 ISOTHERMAL AMPLIFICATION 119
10.4 CLINICS 119
10.4.1 POLYMERASE CHAIN REACTION 120
10.4.2 ISOTHERMAL AMPLIFICATION 120
10.5 AMBULATORY CENTER 120
10.5.1 POLYMERASE CHAIN REACTION 121
10.5.2 ISOTHERMAL AMPLIFICATION 121
10.6 HOMECARE 121
10.6.1 POLYMERASE CHAIN REACTION 122
10.6.2 ISOTHERMAL AMPLIFICATION 122
10.7 ASSISTED LIVING FACILITIES 123
10.7.1 POLYMERASE CHAIN REACTION 123
10.7.2 ISOTHERMAL AMPLIFICATION 123
10.8 OTHERS 124
11 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING 125
11.1 OVERVIEW 126
11.2 PRESCRIPTION-BASED TESTING 129
11.3 OTC TESTING 130
12 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL 131
12.1 OVERVIEW 132
12.2 HOSPITAL PHARMACY 135
12.3 RETAIL PHARMACY 136
12.4 ONLINE PHARMACY 137
13 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION 138
13.1 EUROPE 139
13.1.1 U.K. 149
13.1.2 GERMANY 154
13.1.3 ITALY 159
13.1.4 FRANCE 164
13.1.5 SPAIN 169
13.1.6 REST OF EUROPE 174
14 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY LANDSCAPE 175
14.1 COMPANY SHARE ANALYSIS: EUROPE 175
15 SWOT ANALYSIS 176
16 COMPANY PROFILE 177
16.1 DANAHER 177
16.1.1 COMPANY SNAPSHOT 177
16.1.2 REVENUE ANALYSIS 177
16.1.3 COMPANY SHARE ANALYSIS 178
16.1.4 PRODUCT PORTFOLIO 178
16.1.5 RECENT DEVELOPMENTS 179
16.2 THERMO FISHER SCIENTIFIC INC. 180
16.2.1 COMPANY SNAPSHOT 180
16.2.2 REVENUE ANALYSIS 180
16.2.3 COMPANY SHARE ANALYSIS 181
16.2.4 PRODUCT PORTFOLIO 181
16.2.5 RECENT DEVELOPMENTS 181
16.3 BD 182
16.3.1 COMPANY SNAPSHOT 182
16.3.2 REVENUE ANALYSIS 182
16.3.3 COMPANY SHARE ANALYSIS 183
16.3.4 PRODUCT PORTFOLIO 183
16.3.5 RECENT DEVELOPMENTS 183
16.4 F.HOFFMANN-LA-ROCHE LTD. 184
16.4.1 COMPANY SNAPSHOT 184
16.4.2 REVENUE ANALYSIS 184
16.4.3 COMPANY SHARE ANALYSIS 185
16.4.4 PRODUCT PORTFOLIO 185
16.4.5 RECENT DEVELOPMENTS 186
16.5 ABBOTT 187
16.5.1 COMPANY SNAPSHOT 187
16.5.2 REVENUE ANALYSIS 187
16.5.3 PRODUCT PORTFOLIO 188
16.5.4 RECENT DEVELOPMENTS 188
16.6 BINX HEALTH, INC. 189
16.6.1 COMPANY SNAPSHOT 189
16.6.2 PRODUCT PORTFOLIO 189
16.6.3 RECENT DEVELOPMENT 189
16.7 BIOMERIEUX SA 190
16.7.1 COMPANY SNAPSHOT 190
16.7.2 REVENUE ANALYSIS 190
16.7.3 PRODUCT PORTFOLIO 191
16.7.4 RECENT DEVELOPMENT 191
16.8 CO-DIAGNOSTICS, INC. 192
16.8.1 COMPANY SNAPSHOT 192
16.8.2 REVENUE ANALYSIS 192
16.8.3 PRODUCT PORTFOLIO 193
16.8.4 RECENT DEVELOPMENTS 193
16.9 GENMARK DIAGNOSTICS, INC 194
16.9.1 COMPANY SNAPSHOT 194
16.9.2 REVENUE ANALYSIS 194
16.9.3 PRODUCT PORTFOLIO 195
16.9.4 RECENT DEVELOPMENT 195
16.10 GRIFOLS, S.A. 196
16.10.1 COMPANY SNAPSHOT 196
16.10.2 REVENUE ANALYSIS 196
16.10.3 PRODUCT PORTFOLIO 197
16.10.4 RECENT DEVELOPMENT 197
16.11 LUCIRA HEALTH INC. 198
16.11.1 COMPANY SNAPSHOT 198
16.11.2 PRODUCT PORTFOLIO 198
16.11.3 RECENT DEVELOPMENTS 198
16.12 MERIDIAN BIOSCIENCE 199
16.12.1 COMPANY SNAPSHOT 199
16.12.2 REVENUE ANALYSIS 199
16.12.3 PRODUCT PORTFOLIO 200
16.12.4 RECENT DEVELOPMENTS 200
16.13 QUANTUMDX GROUP LTD. 201
16.13.1 COMPANY SNAPSHOT 201
16.13.2 PRODUCT PORTFOLIO 201
16.13.3 RECENT DEVELOPMENTS 201
16.14 QUIDEL CORPORATION 203
16.14.1 COMPANY SNAPSHOT 203
16.14.2 REVENUE ANALYSIS 203
16.14.3 PRODUCT PORTFOLIO 204
16.14.4 RECENT DEVELOPMENT 204
16.15 SD BIOSENSOR, INC. 205
16.15.1 COMPANY SNAPSHOT 205
16.15.2 PRODUCT PORTFOLIO 205
16.15.3 RECENT DEVELOPMENT 205
16.16 SEKISUI DIAGNOSTICS (A SUBSIDIARY OF SEKISUI MEDICAL) 206
16.16.1 COMPANY SNAPSHOT 206
16.16.2 PRODUCT PORTFOLIO 206
16.16.3 RECENT DEVELOPMENT 206
16.17 SYSMEX (A SUBSIDIARY OF SYSMEX CORPORATION 208
16.17.1 COMPANY SNAPSHOT 208
16.17.2 REVENUE ANALYSIS 208
16.17.3 PRODUCT PORTFOLIO 209
16.17.4 RECENT DEVELOPMENT 209
16.18 WONDFO 210
16.18.1 COMPANY SNAPSHOT 210
16.18.2 PRODUCT PORTFOLIO 210
16.18.3 RECENT DEVELOPMENT 210
17 QUESTIONNAIRE 211
18 RELATED REPORTS 214

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.